Power your movement-disorder trial with fewer patients.
Rating scales carry rater error and ordinal compression in every observation. NeuroQuantix adds a fit-for-purpose kinematic endpoint beside them: one metric, specified a priori for your mechanism, measured from a brief spiral drawing on an iPad and locked in the statistical analysis plan before first patient in. Published reliability up to ICC 0.97 for the implemented metric supports powered studies with a fraction of the subjects rating scales require.
Built for regulatory submission from day one: 21 CFR Part 11, EU GMP Annex 11, GxP, CDISC. Evidence mapped in a scoping review of 120 studies in Movement Disorders Clinical Practice.
One drawing. One pre-specified endpoint. No wearables.
The assessment happens at visits you already have. The endpoint is one metric, specified a priori for your mechanism and locked in the statistical analysis plan, with its concept of interest and context of use documented the way the FDA clinical outcome assessment framework describes. Additional kinematic measures are collected for exploratory analysis and reported as such.
Site burden
A brief drawing assessment on iPad Pro or Wacom digitizer at existing visits. Under 30 minutes to train a site.
Practice effects
A standardized administration protocol that controls practice effects and rater dependence and preserves sensitivity to treatment effects.
Data flow
Audit-trailed capture, CDISC-compatible export, API transfer to your EDC. Built to 21 CFR Part 11 and EU GMP Annex 11.
Protocol details and the shown-versus-validating table are on the platform page and the research page.
Why the endpoint, not the drug, is often what missed
A trained rater assigns one whole number per item, once per visit, with floor and ceiling effects and drift between sites. Everything below a reliability of 1.0 is error the treatment effect has to overcome. Computed kinematics remove the rater from the measurement. The published contrast for essential tremor:
Test-retest reliability up to ICC 0.97 for the velocity spectral peak metric in essential tremor
Haubenberger et al., 2011, Movement DisordersAs few as 9 subjects per arm at 95% power to detect a 50% tremor reduction with the velocity spectral peak metric, versus roughly 25 to 33 per arm with TETRAS
Haubenberger et al., 2011AUC 0.862 for Parkinson disease discrimination with the Composite Index of Speed and Pressure
Zham et al., 2017, Frontiers in NeurologyResponsiveness demonstrated to levodopa on/off transitions, ethanol challenge in ET, focused ultrasound thalamotomy, and DBS
Scoping review, Wang et al., 2025Built for teams that have to defend an endpoint choice
Sponsors: pharma and biotech
Add a pre-specified kinematic endpoint beside TETRAS, MDS-UPDRS, or SARA in the study you are planning now. Exploratory first, secondary as evidence accumulates.
How it enters your trialCROs
Differentiate CNS proposals with an objective motor endpoint that integrates with your EDC and ships with the regulatory documentation your submissions team needs.
Partnership modelResearchers and sites
Partner on psychometric research, use the platform in investigator-initiated work, or get measurement sections and letters for grant applications.
Research collaborationQuestions sponsors ask first
What is NeuroQuantix?
NeuroQuantix is a fit-for-purpose digital clinical outcome assessment for movement disorder trials from Cerebral Innovations LLC. A patient completes a brief drawing assessment on an iPad; one kinematic metric, specified a priori for the drug's mechanism, is the trial endpoint and runs alongside the clinician-rated scale. It is built to 21 CFR Part 11 and EU GMP Annex 11 standards with CDISC-compatible exports.
How does an objective motor endpoint reduce the number of patients a trial needs?
Enrollment is set by measurement error. TETRAS inter-rater reliability is ICC 0.74 to 0.85; the published velocity spectral peak metric reaches ICC 0.97. In the published essential tremor example, that difference is 9 subjects per arm at 95% power versus 25 to 33 with TETRAS for a 50% tremor reduction. Your own numbers depend on the mechanism and the metric pre-specified.
How does NeuroQuantix work alongside TETRAS or MDS-UPDRS?
NeuroQuantix is designed to run alongside the clinician-rated scale that anchors the program, adding continuous, rater-independent measurement of the domain the therapy targets. It enters a program as a pre-specified exploratory or secondary endpoint within the IND, with the evidence for its context of use assembled for the FDA clinical outcome assessment framework and the sponsor's COA dossier.
What does it add to site burden?
A tablet and a stylus at visits you already have: a brief drawing assessment, and under 30 minutes to train a site. No wearables to ship, charge, or recover.
Put NeuroQuantix in your next study
A 20-minute briefing tells you which metric would be pre-specified for your mechanism and what the enrollment math looks like. If it fits, you get a written pilot scope. Both are free.
AI-administered name-to-face recall that measures overnight memory consolidation for Alzheimer disease and cognitive decline trials.